Pri­vate eq­ui­ty firm Per­mi­ra buys phar­ma ser­vice provider Er­gomed in £703.1M deal

Pri­vate eq­ui­ty com­pa­ny Per­mi­ra has ac­quired pub­licly-list­ed phar­ma ser­vice provider Er­gomed in a cash agree­ment worth £703.1 mil­lion ($883 mil­lion), with the deal slat­ed to be­come ef­fec­tive in the first quar­ter of 2024.

“We be­lieve the ac­qui­si­tion will sig­nif­i­cant­ly in­crease our abil­i­ty to in­vest in our com­mer­cial in­fra­struc­ture, tech­nol­o­gy trans­for­ma­tion and to ex­e­cute trans­for­ma­tion­al M&A, in both the CRO and PV busi­ness­es,” said Er­gomed founder Miroslav Rel­janović in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER